Assertio Therapeutics (NASDAQ: ASRT) reported Q3 EPS of $0.01, $0.14 worse than the analyst estimate of $0.15. Revenue for the quarter came in at $35.63 million versus the consensus estimate of $49.92 million.

For earnings history and earnings-related data on Assertio Therapeutics (ASRT) click here.